Table 2.
Clinical features of iatrogenic Kaposi’s sarcoma patients associated with neoplasia
| Patient age/sex | Underlying disease | Immunosuppressive treatment before KS development | Localization (skin lesions) | Extracutaneous involvement | Management of KS | Follow-up (after KS diagnosis) |
|---|---|---|---|---|---|---|
| 1. 53/female | Follicular NHL | CT (fludarabine) | Lower extremity | - | - | Deceased after 1-year follow-up due to lymphoma |
| 2. 81/male | Follicular NHL | SC, CT (unknown regimen) | Torso | - | - | Deceased after 2-month follow-up due to lymphoma |
| 3. 55/female | Myelodysplastic syndrome | SC | Upper and lower extremity | - | Unknown | Lost to follow-up |
| 4. 77/male | Mycosis fungoides (stage 1B) | PUVA, TC (cream) | Lower extremity (solitary) | - | Surgical excision | No relapse in 2-year follow-up, deceased due to another condition |
| 5. 79/male | Mycosis fungoides (stage 1B)* | PUVA, IFN-alpha, acitretin | Lower extremity (solitary) | - | Surgical excision | Relapsed after 2-year follow-up |
| 6. 38/male | Hodgkin lymphoma | CT (ABVD), RT | Upper and lower extremity | Tonsil | Unknown | Lost to follow-up |
| 7. 44/male | Peripheral T-cell lymphoma | CT (CHOP) | Upper and lower extremity, torso, face | - | RT, IFN-alpha, CT (paclitaxel) | Deceased after 1-year follow-up due to lymphoma |
| 8. 54/male | Bladder adenocarcinoma | CT, RT | Lower extremity, face | - | - | Deceased after 2-month follow-up due to another condition |
*With a plaque showing large cell transformation. Patients with thymoma and MG are given in Table 3 TC: Topical corticosteroid, NHL: Non-Hodgkin lymphoma, IFN: Interferon, CT: Chemotherapy, RT: Radiotherapy, ABVD: Adriamycin, bleomycin, vinblastine, doxorubicin, CHOP: Cyclophosphamide, doxorubicin, vincristine, prednisone, SC: Systemic corticosteroid, KS: Kaposi’s sarcoma, PUVA: Psoralen and Ultraviolet A